[Skip to Navigation]
[Skip to Navigation Landing]
September 2016

Measuring the Value of New Medications and Implications for Medicare’s Proposed Part B Drug Payment Model

Author Affiliations
  • 1Faculty of Arts and Sciences, Harvard University, Boston, Massachusetts
  • 2Brigham and Women’s Hospital, Boston, Massachusetts
  • 3PureTech, Boston, Massachusetts
JAMA Oncol. 2016;2(9):1125-1126. doi:10.1001/jamaoncol.2016.2037

Recent scientific advances have yielded promising new treatment options for patients with cancer, but these achievements in translational medicine have been increasingly overshadowed by public controversy because of their cost.1 With the advent of combination immunotherapies whose list prices may exceed $300 000 per year, several drug industry leaders have joined calls for a “more rational” and “sustainable” system of cancer drug pricing.2